Skip to textbook content
Doctor’s PassportTextbook
TopicsAll topics

Loading topic navigation…

Textbook navigation
TopicsAll topics

Loading topic navigation…
Educational draft · awaiting clinical reviewUse Rapid for revision, not patient-care decisions. Check current national and local guidance and the BNF or BNFC before acting.

Pancreatic exocrine insufficiency

Gastroenterology and hepatology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending

RapidFull

Synopsis

Recognise pancreatic maldigestion before advanced malnutrition, identify the pancreatic cause, and optimise enzyme replacement with food, dietetic support and objective nutritional follow-up.

  • Pancreatic exocrine insufficiency is inadequate delivery or activity of digestive enzymes and bicarbonate, causing maldigestion, weight loss and micronutrient consequences.
  • Common settings include chronic pancreatitis, pancreatic cancer, pancreatic resection, cystic fibrosis and severe or necrotising acute pancreatitis; always identify the underlying pancreatic disease.
  • Steatorrhoea is a late and variably recognised sign; bloating, abdominal discomfort, diarrhoea, excess wind, difficulty maintaining weight and fat-soluble vitamin deficiency may appear earlier.
  • Faecal elastase-1 is the practical first-line test when diagnosis is uncertain, but watery stool can dilute the sample and a low result does not reveal the cause.
  • In a high-probability setting such as pancreatic cancer or major pancreatic resection, do not withhold enzyme treatment while waiting for an imperfect faecal test.
  • Pancreatic enzyme replacement therapy must be taken with every fat- or protein-containing meal, snack and nutritional supplement, spread through eating to mix with chyme.
  • Do not routinely prescribe a low-fat diet because it can worsen energy deficiency; optimise enzymes and use a pancreatic specialist dietitian instead.
  • If response is incomplete, check timing, dose, supply, adherence and gastric acidity, then investigate alternative or additional causes rather than escalating indefinitely.

    • Key red flags

    New painless jaundice, progressive weight loss, palpable gallbladder or new diabetes with pancreatic symptoms requires urgent pancreatic cancer assessment rather than PERT alone.

    Severe abdominal pain, vomiting, fever or haemodynamic disturbance needs acute pancreatitis, obstruction, cholangitis and other emergency assessment.

    Rapid nutritional decline, dehydration, profound vitamin deficiency or inability to tolerate oral intake warrants urgent dietetic and specialist nutrition support.

    A high-risk patient who cannot obtain PERT because of supply disruption needs same-day pharmacy and specialist substitution advice; missed treatment can quickly worsen nutrition.

    New obstructive symptoms on very high pancreatin exposure require review because rare fibrosing colonopathy has been associated particularly with high-dose use in cystic fibrosis.

    Investigation priorities

    01
    Faecal elastase-1First step

    Estimate pancreatic exocrine secretion using a practical non-invasive stool test.

    Management branches

    DIAGNOSEConfirm PEI without missing the cause

    Maldigestion, nutritional decline or a high-risk pancreatic condition raises suspicion of exocrine failure.

    1. Clarify stool character, weight, diet, alcohol, smoking, pancreatitis, surgery, cancer symptoms, diabetes and current enzyme timing, then examine nutrition and jaundice.
    2. Use formed-stool faecal elastase when uncertainty remains, while commencing PERT empirically in a high-probability condition where delay would harm nutrition.
    3. Obtain pancreatic imaging or urgent cancer-pathway review appropriate to presentation; enzyme deficiency is never a substitute label for obstructing anatomy.
    4. Measure nutritional, micronutrient, glucose and bone consequences and refer to a pancreatic specialist dietitian.

    Key medicines

    Pancreatin pancreatic enzyme replacementUsually start at least 50,000 lipase units with meals and 25,000 with snacks, then titrate.Take throughout food, confirm product strength, do not crush enteric-coated granules, review porcine allergy and very high-dose risks, and follow current supply-substitution advice.
    Proton pump inhibitor adjunctStandard licensed acid-suppression regimen trialled after adequate PERT timing and dose review.Do not use as a substitute for sufficient enzymes; review indication and long-term magnesium, infection, fracture and interaction risks according to individual exposure.
    Open full textbook →Answer 2 questions
    Sources and review status6 sources · checked 27 Aug 2026 · clinical review pending+
    Sources

    Sources and review status

    National guidance is shown before implementation-dependent detail. Typical adult dose examples remain subject to patient factors, contraindications and the live BNF or specialist protocol. Source check completed 27 Aug 2026; clinical approval remains outstanding.

    • UK practical guideline for pancreatic exocrine insufficiencyUK pancreatic-specialist consensus on diagnosis, PERT and follow-up.
    • NICE QS177 Pancreatic enzyme replacementQuality standard for enzyme treatment in pancreatic cancer.
    • NICE BNF Exocrine pancreatic insufficiencyBritish prescribing role and available pancreatin preparations.
    • Creon 25000 UK SmPCCurrent July 2026 licensed administration, storage and adverse effects.
    • PSGBI pancreatic enzyme shortage statementCurrent UK specialist advice for supply disruption and substitution.
    • BSG Chronic pancreatitis practical guideUnderlying chronic pancreatic disease, malnutrition and multidisciplinary care.

    Editorial contact: Doctor’s Passport editorial team. Source-check date is separate from clinical approval. Report a content problem · Content changes

    Authoring stateRapid draftClinical stateAwaiting reviewJurisdictionUnited Kingdom